409 filings
Page 10 of 21
8-K
7d1pcyk 80
20 May 14
Other Events
12:00am
8-K
5f8w2u h43bvkc9
20 May 14
Bronchodilator response to the long-acting bronchodilator combination of umeclidinium/vilanterol across subgroups of patients with COPD
12:00am
8-K
hmgvlevyie4
19 May 14
Other Events
12:00am
8-K
gr6nt7x2y9mdc5 by7
15 May 14
Other Events
12:00am
8-K
7fok79ki03qd fhgw
8 May 14
Other Events
12:00am
8-K
nwkp 6yf2
8 May 14
Departure of Directors or Certain Officers
12:00am
8-K
mh575l
6 May 14
Results of Operations and Financial Condition
12:00am
8-K
91d7mveg
5 May 14
Departure of Directors or Certain Officers
12:00am
8-K
zwuzo8z6ax
2 May 14
Regulation FD Disclosure
12:00am
8-K
aj8mk2f2 m6cmj
30 Apr 14
Theravance Announces Positive Results From a Phase 2 Study of TD-9855 in Patients With Fibromyalgia
12:00am
8-K
wadcz59bqpl67 dz
28 Apr 14
Financial Statements and Exhibits
12:00am
8-K
rhh43t f8
22 Apr 14
Breo™Ellipta® (fluticasone furoate/vilanterol trifenatate) approved in Australia for Asthma and Chronic Obstructive Pulmonary Disease
12:00am
8-K
2mgce o3k9onf
21 Apr 14
Theravance Closes Private Placement of $450 Million of 9% Non-Recourse Notes Supporting Strategic Separation Process
12:00am
8-K
xyrlvay
9 Apr 14
Regulation FD Disclosure
12:00am
8-K
j71cogwsbl
24 Mar 14
Regulation FD Disclosure
12:00am
8-K
m8hmafmo3cd1r
18 Mar 14
Other Events
12:00am
8-K
synkeu
14 Mar 14
Other Events
12:00am
8-K
rjx3rpjkg8hao8y0ma
13 Mar 14
Other Events
12:00am
8-K/A
glzu5hx ew5jnu
6 Mar 14
Entry into a Material Definitive Agreement
12:00am
8-K
qqsls5d9r01
3 Mar 14
Theravance Announces Update to Planned Separation of Late-Stage Partnered Respiratory Assets from Biopharmaceutical Operations
12:00am